Protara Therapeutics, Inc. Common Stock TARA
$3.85
+0.92%
at last close
Market Cap$225.74 million
P/E Ratio—
Div Yield—
Volume375.7K
52-Week Range
$2.97$7.82
Analyst Ratings
- Consensus
- Buy — 4 Buy · 0 Hold · 0 Sell (4 analysts)
- Avg. Price Target
- $26.25 (+580.9% upside)
Key Stats
- Today's Range
- $3.72 – $3.88
- 50-Day Range
- $3.71 – $4.49
- 52-Week Range
- $2.97 – $7.82
- Volume
- 376K shs
- Average Volume
- 379K shs
- Market Cap
- $225.74 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 1.40
- Price / Sales
- 71.98
Short Interest
- Short Interest
- 0.01%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $3.14 million
- Net Income
- $-70,015,000
- Net Margin
- -2232.62%
- Return on Equity
- -43.40%
- Debt-to-Equity
- —
About Protara Therapeutics, Inc. Common Stock
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
Related Stocks
Compare head-to-head: TARA vs AMGN·TARA vs MRNA·TARA vs HALO·TARA vs KRYS
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.